x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

QCast: Data-Driven Dialogue in Drug Development

QCast by Quanticate is the podcast for biotech, pharma, and life science leaders looking to deepen their understanding of biometrics and modern drug development. Join co-hosts Tom and Jullia as they explore methodologies, case studies, regulatory shifts, and industry trends shaping the future of clinical research. Where biometric expertise meets data-driven dialogue, QCast delivers practical insights and thought leadership to inform your next breakthrough.

science life sciences

All Episodes

10:04

Episode 42: Medical Device Clinical Trials

QCast: Data-Driven Dialogue in Drug Development ·

2026/04/17

In this QCast episode, Jullia and Tom explore medical device clinical trials and why they differ in important ways from drug studies. They explain what these trials are designed to show, how safety, performance, and clinical benefit are assessed across different types of devices, and why study design depends so heavily on intended use, risk profile, usability, and real-world clinical context.Key TakeawaysUnderstand medical device clinical trials as evidence-generating studies built around safety,

en-gb

8:19

Episode 41: What Are SAD MAD Studies?

QCast: Data-Driven Dialogue in Drug Development ·

2026/04/10

In this QCast episode, Jullia and Tom explore SAD and MAD studies and why they play such a central role in early clinical development. They explain what single ascending dose and multiple ascending dose studies are designed to show, how they help teams build an early picture of safety, tolerability, and pharmacokinetics, and why their value depends on clear escalation rules, fast data review, and disciplined study execution.Key TakeawaysUnderstand SAD and MAD studies as core early-phase designs used

en-gb

12:31

Episode 40: Functional Service Provision (FSP)

QCast: Data-Driven Dialogue in Drug Development ·

2026/04/03

In this QCast episode, Jullia and Tom explore functional service provision and why it remains such an important outsourcing model in clinical development. They explain what FSP means in practical terms, how it differs from full-service delivery, where it can give sponsors more flexibility and specialist support, and why its success depends on clear scope, strong governance, and effective oversight.Key TakeawaysUnderstand functional service provision as a model where sponsors outsource defined

en-gb

12:02

Episode 39: Automation in Clinical Trials

QCast: Data-Driven Dialogue in Drug Development ·

2026/03/27

In this QCast episode, Jullia and Tom explore automation in clinical trials and why it matters for modern study delivery. They explain what automation looks like in day-to-day trial work, where it can reduce manual burden across consent, data flow, query management, and oversight, and why its value depends on strong integration, governance, and human review.Key TakeawaysUnderstand automation as the use of connected digital systems to support repeatable trial tasks with greater consistency and

en-gb

11:01

Episode 38: Observational Studies in Clinical Trials

QCast: Data-Driven Dialogue in Drug Development ·

2026/03/20

In this QCast episode, Jullia and Tom explore observational studies and why they remain such an important part of the evidence base in drug development. They explain what makes an observational study different from an interventional trial, how routine care data can be used to answer practical research questions, and why the value of these studies depends so heavily on clear design, data quality, and careful analysis.Key TakeawaysUnderstand observational studies as non-interventional research, where

en-gb

11:01

Episode 37: Phase 2b in Clinical Trials

QCast: Data-Driven Dialogue in Drug Development ·

2026/03/13

In this QCast episode, Jullia and Tom explore phase 2b in clinical trials and why this stage plays such a decisive role in moving a programme towards phase 3. They explain how phase 2b is typically used to reduce uncertainty around dose, population, endpoints, and treatment effect, and why the study needs to produce data that can support a real development decision rather than just an encouraging signal.Key TakeawaysTreat phase 2b as a focused decision study, with design choices centred on whether

en-gb

11:08

Episode 36: ACR Response Criteria in Rheumatoid...

QCast: Data-Driven Dialogue in Drug Development ·

2026/03/06

In this QCast episode, Jullia and Tom unpack ACR response criteria in rheumatoid arthritis clinical trials and why these endpoints are more operationally demanding than they look on paper. They explain what ACR20, ACR50, and ACR70 measure, how the responder definition depends on consistent joint counts, patient-reported assessments, and timely acute phase reactants, and why a clean-looking binary endpoint can still carry composite-style risks.Key TakeawaysProtect the core ACR components at site

en-gb

11:16

Episode 35: Regulatory Submissions in Clinical Trials

QCast: Data-Driven Dialogue in Drug Development ·

2026/02/27

In this QCast episode, Jullia and Tom explore regulatory submissions in clinical trials and why strong submission discipline protects timelines long before any scientific review begins. They discuss what a regulatory submission includes in practice, how early technical validation and portal expectations can derail an otherwise solid package, and where teams most often lose time through version drift, misaligned dependencies, and avoidable publishing and metadata errors.Key TakeawaysTreat technical

en-gb

11:56

Episode 34: Therapeutic Areas in Clinical Research

QCast: Data-Driven Dialogue in Drug Development ·

2026/02/20

In this QCast episode, Jullia and Tom unpack therapeutic areas in clinical research and why they matter far beyond a clinical label. They discuss how a therapeutic area shapes trial design assumptions, from endpoint selection and safety oversight to site models, specialist assessments, and the way data moves from collection to review and analysis.Key TakeawaysRecognise how therapeutic area choice influences endpoint strategy, safety review cadence, site workflows, and vendor needs from the earliest

en-gb

11:19

Episode 33: eCRF Design in Clinical Trials

QCast: Data-Driven Dialogue in Drug Development ·

2026/02/13

In this QCast episode, Jullia and Tom break down eCRF design in clinical trials and why it has such an outsized impact on data quality, site workload, and downstream analysis. They clarify what an electronic case report form is meant to do in practice, how it translates protocol requirements into usable data capture, and how to approach validation checks without overburdening sites.Key TakeawaysUnderstand what eCRF design is and how it supports consistent, high-integrity data capture in an

en-gb

11:30

Episode 32: Risk-Based Quality Management in CDM

QCast: Data-Driven Dialogue in Drug Development ·

2026/02/06

In this QCast episode, Jullia and Tom unpack risk-based quality management (RBQM) in clinical data management and why it’s central to protecting participant safety and the reliability of trial results. They clarify what RBQM means in practice, how teams identify critical data and processes, and how KRIs and QTLs can be used to spot emerging issues early and drive proportionate, documented action across functions.Key TakeawaysUnderstand what RBQM is in a clinical data management context, and how it

en-gb

11:29

Episode 31: Investigator's Brochure (IB)

QCast: Data-Driven Dialogue in Drug Development ·

2026/01/30

In this QCast episode, Jullia and Tom break down the Investigator’s Brochure (IB) and why it remains a cornerstone of safe, consistent trial conduct. They explain what an IB is, who relies on it, and how it complements the protocol by translating the evolving evidence base into practical guidance on dosing rationale, monitoring, and risk management.Key Takeaways Understand what an Investigator’s Brochure is, who it’s for, and how it supports risk and benefit assessment alongside the protocol. Learn

en-gb

12:49

Episode 30: Adaptive Randomisation in Clinical Trials

QCast: Data-Driven Dialogue in Drug Development ·

2026/01/23

In this QCast episode, Jullia and Tom unpack adaptive randomisation in clinical trials and why teams consider it when fixed allocation feels inefficient or ethically uncomfortable. They explain how response-adaptive randomisation can shift treatment assignment as evidence accumulates, and how patient characteristics can be incorporated through covariate-adjusted response-adaptive randomisation. Key TakeawaysUnderstand what adaptive randomisation is, how it differs from fixed randomisation, and where

en-gb

9:44

Episode 29: What is Clinical Data Management?

QCast: Data-Driven Dialogue in Drug Development ·

2026/01/16

In this QCast episode, Jullia and Tom break down what clinical data management is and why it’s essential to reliable trial decisions. They explain how clinical data management supports patient safety and data integrity from study start-up through to database lock, covering core activities like CRF design, database build, validation checks, query management, reconciliation of external data, and inspection-ready documentation.Key TakeawaysUnderstand what clinical data management covers end to end, and

en-gb

9:18

Episode 28: Real World Data Analysis in Clinical Trials

QCast: Data-Driven Dialogue in Drug Development ·

2026/01/09

In this QCast episode, Jullia and Tom unpack how real world data is analysed to complement clinical trials. They clarify the difference between real world data and real world evidence, explore the main data sources and their trade-offs, and explain how these datasets support trial decisions across feasibility, effectiveness in routine care, and longer-term safety.Key TakeawaysUnderstand the difference between real world data and real world evidence, and why real world analysis is increasingly used

en-gb

10:45

Episode 27: Machine Learning in the Pharmaceutical...

QCast: Data-Driven Dialogue in Drug Development ·

2025/12/26

In this QCast episode, Jullia and Tom unpack how machine learning is being applied across the pharmaceutical industry. They discuss what machine learning means in a regulated drug development context, where it is already supporting discovery, development, and trial operations, and how teams can use these methods responsibly without undermining scientific or regulatory confidence.Key TakeawaysUnderstand how machine learning differs from traditional statistical approaches, and why it is particularly

en-gb

9:29

Episode 26: Medical Coding in Clinical Data Management

QCast: Data-Driven Dialogue in Drug Development ·

2025/12/22

In this QCast episode, Jullia and Tom explore medical coding in clinical data management, clarifying how clinical narratives are translated into standardised terminology, why consistent coding underpins safety review and regulatory confidence, and how coding decisions shape analysis-ready datasets across a study’s lifecycle.Key TakeawaysUnderstand how medical coding aligns adverse events, medical history, and medications using controlled dictionaries to support reliable aggregation and

en-gb

11:28

Episode 25: The Proportional Odds Assumption in...

QCast: Data-Driven Dialogue in Drug Development ·

2025/12/12

In this QCast episode, Jullia and Tom unpack the proportional odds assumption in ordinal logistic regression, explaining what it means in practice, why it matters for ordinal endpoints in clinical trials, and how to diagnose and handle violations without losing the value of ordered scales.Key TakeawaysUnderstand that proportional odds implies a single treatment effect across all cut points of an ordered endpoint, enabling an efficient summary of benefit.Examine outcome distributions, use formal

en-gb

10:43

Episode 24: Health Economics and Outcomes Research...

QCast: Data-Driven Dialogue in Drug Development ·

2025/12/05

In this QCast episode, Jullia and Tom explore health economics and outcomes research, explaining how outcomes research looks beyond controlled trials to real world care and how HEOR evidence informs pricing, reimbursement, and access decisions.Key TakeawaysAnchor HEOR work to a clear decision question around value, pricing, access, or policy.Match methods to the data: define cohorts carefully, respect real world data limits, and invest in strong database infrastructure and quality control.Plan for

en-gb

10:54

Episode 23: Query Management in Clinical Trials

QCast: Data-Driven Dialogue in Drug Development ·

2025/11/28

In this QCast episode, Jullia and Tom unpack query management in clinical trials, outlining what queries are, how they move from detection to closure, and how thoughtful design, clear communication, and focused metrics turn them from administrative noise into a practical quality tool that protects data integrity, timelines, and inspection readiness.Key TakeawaysDefine query management as part of study design, not just an operational clean up activity.Use clear, targeted edit checks and concise query

en-gb

42 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter